期刊
ALLERGY
卷 66, 期 11, 页码 1397-1406出版社
WILEY
DOI: 10.1111/j.1398-9995.2011.02686.x
关键词
angioedema; bradykinin; C1 esterase inhibitor; icatibant
资金
- Shire Human Genetic Therapies Inc.
- Jerini AG
- Jerini AG/Shire Human Genetic Therapies Inc.
Bradykinin has been implicated to contribute to allergic inflammation and the pathogenesis of allergic conditions. It binds to endothelial B-1 and B-2 receptors and exerts potent pharmacological and physiological effects, notably, decreased blood pressure, increased vascular permeability and the promotion of classical symptoms of inflammation such as vasodilation, hyperthermia, oedema and pain. Towards potential clinical benefit, bradykinin has also been shown to exert potent anti-thrombogenic, antiproliferative and antifibrogenic effects. The development of pharmacologically active substances, such as bradykinin receptor blockers, opens up new therapeutic options that require further research into bradykinin. This review presents current understanding surrounding the role of bradykinin in nonallergic angioedema and other conditions seen by allergists and emergency physicians, and its potential role as a therapeutic target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据